메뉴 건너뛰기




Volumn 13, Issue 8, 2012, Pages 744-745

The coming of age of MEK

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; TRAMETINIB; VEMURAFENIB;

EID: 84864327137     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70317-0     Document Type: Letter
Times cited : (7)

References (11)
  • 1
    • 31144453233 scopus 로고    scopus 로고
    • BRAF mutation predicts sensitivity to MEK inhibition
    • Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
    • (2006) Nature , vol.439 , pp. 358-362
    • Solit, D.B.1    Garraway, L.A.2    Pratilas, C.A.3
  • 2
    • 77949568748 scopus 로고    scopus 로고
    • Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
    • Drosten M, Dhawahir A, Sum EY, et al. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J 2010, 29:1091-1104.
    • (2010) EMBO J , vol.29 , pp. 1091-1104
    • Drosten, M.1    Dhawahir, A.2    Sum, E.Y.3
  • 3
    • 0037805547 scopus 로고    scopus 로고
    • RAS oncogenes: the first 30 years
    • Malumbres M, Barbacid M RAS oncogenes: the first 30 years. Nat Rev Cancer 2003, 3:459-465.
    • (2003) Nat Rev Cancer , vol.3 , pp. 459-465
    • Malumbres, M.1    Barbacid, M.2
  • 4
    • 77956030786 scopus 로고    scopus 로고
    • Inhibition of mutated, activated BRAF in metastatic melanoma
    • Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
    • (2010) N Engl J Med , vol.363 , pp. 809-819
    • Flaherty, K.T.1    Puzanov, I.2    Kim, K.B.3
  • 5
    • 84861083983 scopus 로고    scopus 로고
    • Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
    • Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901.
    • (2012) Lancet , vol.379 , pp. 1893-1901
    • Falchook, G.S.1    Long, G.V.2    Kurzrock, R.3
  • 6
    • 74849109743 scopus 로고    scopus 로고
    • Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
    • Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
    • (2010) Cell , vol.140 , pp. 209-221
    • Heidorn, S.J.1    Milagre, C.2    Whittaker, S.3
  • 7
    • 79952261716 scopus 로고    scopus 로고
    • GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition
    • Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011, 17:989-1000.
    • (2011) Clin Cancer Res , vol.17 , pp. 989-1000
    • Gilmartin, A.G.1    Bleam, M.R.2    Groy, A.3
  • 8
    • 84864340896 scopus 로고    scopus 로고
    • Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
    • published online July 16.
    • Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 2012, published online July 16. http://dx.doi.org/10.1016/S1470-2045(12)70270-X.
    • (2012) Lancet Oncol
    • Infante, J.R.1    Fecher, L.A.2    Falchook, G.S.3
  • 9
    • 84864371119 scopus 로고    scopus 로고
    • Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
    • published online July 16.
    • Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012, published online July 16. http://dx.doi.org/10.1016/S1470-2045(12)70269-3.
    • (2012) Lancet Oncol
    • Falchook, G.S.1    Lewis, K.D.2    Infante, J.R.3
  • 10
    • 84863673204 scopus 로고    scopus 로고
    • Improved survival with MEK inhibition in BRAF-mutated melanoma
    • for the METRIC Study Group, Published online June 4.
    • Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, for the METRIC Study Group, Published online June 4. 10.1056/NEJMoa1203421.
    • (2012) N Engl J Med
    • Flaherty, K.T.1    Robert, C.2    Hersey, P.3
  • 11
    • 84863116743 scopus 로고    scopus 로고
    • Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
    • Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714.
    • (2012) N Engl J Med , vol.366 , pp. 707-714
    • Sosman, J.A.1    Kim, K.B.2    Schuchter, L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.